Drug Approval | August 12, 2021
SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
If approved it will bring a second source of MMR vaccine to the US market
The drug is indicated for mild and transient episodes of heart block
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
The company expects revenue growth of 10-15 per cent in the US
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
CDSCO to fast-track trials and approval for COVID19 vaccine
Subscribe To Our Newsletter & Stay Updated
